Key regions: Australia, Germany, United Kingdom, United States, France
The Immunosuppressants market in United Arab Emirates has been experiencing a steady growth in recent years.
Customer preferences: The demand for Immunosuppressants in United Arab Emirates is driven by an aging population, an increase in the number of organ transplants, and a rise in the prevalence of autoimmune diseases. Patients suffering from autoimmune diseases such as rheumatoid arthritis, lupus, and multiple sclerosis require Immunosuppressants to suppress their immune system and prevent their body from attacking itself.
Trends in the market: The Immunosuppressants market in United Arab Emirates is expected to continue growing due to the increasing prevalence of autoimmune diseases. The market is also being driven by the development of new Immunosuppressants, which are more effective and have fewer side effects than traditional Immunosuppressants. Additionally, the demand for Immunosuppressants is expected to rise due to the increasing number of organ transplants being performed in the country.
Local special circumstances: The healthcare system in United Arab Emirates is well-developed, with a large number of hospitals and clinics providing high-quality medical care. The government has also been investing heavily in healthcare infrastructure, which has led to an increase in the number of hospitals and clinics in the country. This has made it easier for patients to access medical care, including Immunosuppressants.
Underlying macroeconomic factors: The economy of United Arab Emirates is highly dependent on oil exports, which has led to a significant amount of wealth being generated in the country. This has allowed the government to invest heavily in healthcare infrastructure, which has led to an increase in the availability of medical care, including Immunosuppressants. Additionally, the government has implemented policies to encourage the development of the healthcare sector, which has led to an increase in the number of pharmaceutical companies operating in the country. This has led to increased competition in the Immunosuppressants market, which has helped to drive down prices and make the drugs more affordable for patients.
Data coverage:
Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.Modeling approach / Market size:
Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.Forecasts:
In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.Additional notes:
Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.
Mon - Fri, 9am - 6pm (EST)
Mon - Fri, 9am - 5pm (SGT)
Mon - Fri, 10:00am - 6:00pm (JST)
Mon - Fri, 9:30am - 5pm (GMT)
Mon - Fri, 9am - 6pm (EST)
